Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumasiran - Alnylam Pharmaceuticals

Next Previous
Drug Profile

Lumasiran - Alnylam Pharmaceuticals

Alternative Names: ALN-GO1; Lumasiran; OXLUMO; Oxlumo

Latest Information Update: 09 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Medison Pharma
  • Class Amino sugars; Drug conjugates; Small interfering RNA; Uricosurics; Urologics
  • Mechanism of Action Glycolate oxidase expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria type 1
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Primary hyperoxaluria type 1
  • Phase II Urinary calculi

Most Recent Events

  • 02 Jul 2025 Launched for Primary hyperoxaluria type 1 (In neonates, In infants, In children, In adolescents, In adults) in Canada (SC)
  • 23 Jun 2025 Alnylam Pharmaceuticals completes a phase III ILLUMINATE-C trial for Primary hyperoxaluria in Belgium, France, Germany, Netherlands, Australia, the US, Israel, Jordan, Lebanon, Switzerland, Turkey, UAE, the UK, Egypt, and India (NCT04152200) (EudraCT2019-001346-17)
  • 26 Apr 2025 Adverse events data from a phase II OLE trial in Primary hyperoxaluria type 1 presented at the 120th Annual Meeting of the American Urological Association (AUA-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top